| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.08. | Zentalis Pharmaceuticals closes $92.6 million stock offering | 1 | Investing.com | ||
| 17.08. | Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 124 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an investigational... ► Artikel lesen | |
| 14.08. | Zentalis Aktie bricht nach Kapitalerhöhung mit hohem Abschlag ein | 1 | Investing.com Deutsch | ||
| 14.08. | Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share | 1 | Seeking Alpha | ||
| 14.08. | Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 | 1 | Investing.com | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering | 2 | GlobeNewswire (USA) | ||
| 13.08. | Stocks to watch on Thursday after hours: AMAT, DLO, ZNTL | 8 | Seeking Alpha | ||
| 13.08. | Zentalis Pharmaceuticals Aktie fällt nach Ankündigung eines öffentlichen Angebots | 1 | Investing.com Deutsch | ||
| 13.08. | Zentalis Pharmaceuticals kündigt öffentliche Aktienplatzierung an | 1 | Investing.com Deutsch | ||
| 13.08. | Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering | 1 | GlobeNewswire (USA) | ||
| 06.08. | Zentalis Pharmaceuticals GAAP EPS of -$0.59 misses by $0.10 | 2 | Seeking Alpha | ||
| 03.08. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 17.07. | Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | 3 | GlobeNewswire (USA) | ||
| 17.07. | Mizuho initiates Zentalis Pharmaceuticals stock at Outperform | 3 | Investing.com | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 22.05. | H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data | 1 | Investing.com | ||
| 22.05. | H.C. Wainwright bestätigt Kaufempfehlung für Zentalis nach Daten zu Eierstockkrebs | 27 | Investing.com Deutsch | ||
| 22.05. | Zentalis to present ovarian cancer trial data at ASCO meeting | 2 | Investing.com | ||
| 21.05. | Zentalis präsentiert auf Jährlicher ASCO-Tagung Studiendaten zu Eierstockkrebs | 2 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 119,06 | -0,03 % | Moderna explodiert 177 gelingt jetzt das große Comeback? | ||
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| ALDEYRA | 1,290 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| GUARDANT HEALTH | 138,50 | -0,69 % | Final judgement favours TwinStrand in Guardant patent case | ||
| TRAWS PHARMA | 0,590 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,050 | +0,56 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,215 | 0,00 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| VERASTEM | 6,280 | +0,71 % | Mizuho lowers Verastem stock price target on valuation to $13 |